Evidence map›Paper›PMID 29371637›Full record

ReviewCell death & disease2018

Cell death-based approaches in treatment of the urinary tract-associated diseases: a fight for survival in the killing fields.

Diego Martin-Sanchez, Miguel Fontecha-Barriuso, Maria Dolores Sanchez-Niño, Adrian M Ramos, Ramiro Cabello, Carmen Gonzalez-Enguita, Andreas Linkermann, Ana Belén Sanz, Alberto Ortiz

Open access · goldAbstract readReview
In one paragraph

Review in Cell death & disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Roles of ferroptosis in urologic malignancies.Cancer cell international · 2021
    Review
  14. Programmed cell death, redox imbalance, and cancer therapeutics.Apoptosis : an international journal on programmed cell death · 2021
    Review
  15. Article
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Diego Martin-SanchezResearch Institute-Fundacion Jimenez Diaz, Autonoma University, Madrid, Spain.
Miguel Fontecha-BarriusoResearch Institute-Fundacion Jimenez Diaz, Autonoma University, Madrid, Spain.
Maria Dolores Sanchez-NiñoResearch Institute-Fundacion Jimenez Diaz, Autonoma University, Madrid, Spain.
Adrian M RamosResearch Institute-Fundacion Jimenez Diaz, Autonoma University, Madrid, Spain.
Ramiro CabelloResearch Institute-Fundacion Jimenez Diaz, Autonoma University, Madrid, Spain.
Carmen Gonzalez-EnguitaResearch Institute-Fundacion Jimenez Diaz, Autonoma University, Madrid, Spain.
Andreas LinkermannDepartment of Internal Medicine III, Division of Nephrology, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany.ORCID 0000-0001-6287-9725
Ana Belén SanzResearch Institute-Fundacion Jimenez Diaz, Autonoma University, Madrid, Spain. asanz@fjd.es.
Alberto OrtizResearch Institute-Fundacion Jimenez Diaz, Autonoma University, Madrid, Spain. aortiz@fjd.es.ORCID 0000-0002-9805-9523
Spanish Clinical Research Network · ESFundación Sandra Ibarra de Solidaridad Frente al Cáncer · ESHospital Universitario Fundación Jiménez Díaz · ESUniversity Hospital Carl Gustav Carus · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Urinary tract-associated diseases comprise a complex set of disorders with a variety of etiologic agents and therapeutic approaches and a huge global burden of disease, estimated at around 1 million deaths per year. These diseases include cancer (mainly prostate, renal, and bladder), urinary tract infections, and urolithiasis. Cell death plays a key role in the pathogenesis and therapy of these conditions. During urinary tract infections, invading bacteria may either promote or prevent host cell death by interfering with cell death pathways. This has been studied in detail for uropathogenic E. coli (UPEC). Inhibition of host cell death may allow intracellular persistence of live bacteria, while promoting host cell death causes tissue damage and releases the microbes. Both crystals and urinary tract obstruction lead to tubular cell death and kidney injury. Among the pathomechanisms, apoptosis, necroptosis, and autophagy represent key processes. With respect to malignant disorders, traditional therapeutic efforts have focused on directly promoting cancer cell death. This may exploit tumor-specific characteristics, such as targeting Vascular Endothelial Growth Factor (VEGF) signaling and mammalian Target of Rapamycin (mTOR) activity in renal cancer and inducing survival factor deprivation by targeting androgen signaling in prostate cancer. An area of intense research is the use of immune checkpoint inhibitors, aiming at unleashing the full potential of immune cells to kill cancer cells. In the future, this may be combined with additional approaches exploiting intrinsic sensitivities to specific modes of cell death such as necroptosis and ferroptosis. Here, we review the contribution of diverse cell death mechanisms to the pathogenesis of urinary tract-associated diseases as well as the potential for novel therapeutic approaches based on an improved molecular understanding of these mechanisms.

Indexed as

ApoptosisAnimalsCell SurvivalCytoskeletonHumansImmunotherapySignal TransductionUrinary Tract Infections

Identifiers

PMID29371637
PMCPMC5833412
OpenAlexW2789924078

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.